Serds At The Inflection Point In Pretreated Er+/Her2- Breast Cancer: Novel Er-Targeting Therapies

SERDs at the Inflection Point in Pretreated ER+/HER2- Breast Cancer: Novel ER-Targeting Therapies

PeerView Oncology

The role of SERDs in the treatment landscape of patients with ER+/HER2- breast cancer

Navigating the Expanding Treatment Arsenal for ER+/HER2- Breast Cancer

PeerView Oncology

Expanding Treatment Options in ER+/HER2- Breast Cancer: SERDs, SERMs, SERCAs, and More

PeerView Oncology

Sequencing Treatment Options in HER2 Positive Breast Cancer: 2023 Best of Breast Conference

Total Health | Oncology

SERDs for patients with ER+/HER2- breast cancer

Estrogen signaling in breast cancer

Science in Motion

Sequencing HER2-targeted therapies in breast cancer

Sequencing novel HER2-targeted therapies in metastatic breast cancer

Metastatic HER2 Negative Breast Cancer: Emerging Novel Treatment Strategies

Total Health | Oncology

ER-Positive Breast Cancer: What's New in Treatment and Research at MBC Patient Forum 2019

Dana-Farber Cancer Institute

HER2 In Breast Cancer: Testing Guidelines and New Treatment Approaches

ASCP

Adjuvant Therapy | 2023 Best of Breast Conference

Total Health | Oncology

GS2-02: "Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s..."

San Antonio Breast Cancer Symposium

Key trial updates in SERDs in ER+/HER2- breast cancer from SABCs 2022

What does the future hold for SERDs in ER+ breast cancer?

Novel targeted therapies in breast cancer

Treatment Updated for HER2 Positive Breast Cancer: Changing Paradigms

Total Health | Oncology

HER2 Positive Breast Cancer: Everything You Must Know

Breast Cancer School for Patients

HER2-Low Expression in Breast Cancer: Opportunities for Expanding Treatment Benefit to More Patients

PeerView Oncology